Related Experiment Video

Updated: Mar 29, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Recent advances in the development of Aurora kinases inhibitors in hematological malignancies

Iqra Choudary1, Paul M Barr2, Jonathan Friedberg2

  • 1University of Rochester - James P. Wilmot Cancer Center, 601 Elmwood Ave, Rochester NY 14642, USA.

Therapeutic Advances in Hematology
|December 2, 2015
PubMed

Insights

Aurora kinase inhibitors show therapeutic potential for hematologic malignancies. Ongoing clinical trials are evaluating their efficacy in treating various blood cancers.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Aurora kinases (A, B, and C) are crucial regulators of the mitotic cell cycle, particularly at chromosomal and cytoskeletal structures.
  • Dysregulation of Aurora kinases is implicated in the development of various cancers.
  • Aurora kinase inhibitors are being investigated as a novel therapeutic strategy.

Purpose of the Study:

  • To review the preclinical and clinical development of Aurora kinase inhibitors.
  • To discuss the therapeutic potential of these inhibitors in hematologic malignancies.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of ongoing clinical trials (Phase I and II).
  • Focus on Aurora kinase inhibitors targeting hematologic cancers.

Main Results:

  • Multiple Aurora kinase inhibitors are in various stages of clinical development.
  • Preclinical data suggest significant anti-cancer activity.
  • Clinical trials are assessing safety and efficacy in hematologic malignancies.

Conclusions:

  • Aurora kinase inhibitors represent a promising class of drugs for hematologic cancers.
  • Further clinical investigation is warranted to establish their role in cancer therapy.
  • Targeting Aurora kinases offers a potential new avenue for treating blood-related malignancies.
Keywords:
Aurora A kinase inhibitorAurora B kinase inhibitorAurora kinase inhibitorsacute myeloid leukemiamultiple myelomanon-Hodgkin’s lymphoma

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
640